Not behind a pay wall
(NewsNation) — Eli Lilly announced Thursday its experimental weight-loss pill passed its first late-stage trial among patients with diabetes, delivering on the company’s promise to lower blood sugar and body weight like other GLP-1 drugs such as Ozempic and Wegovy. Lilly’s Phase 3 trial showed that Type 2 diabetes patients lost an average of 16 pounds, or nearly … Read more
Eli Lilly (LLY) CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald Trump’s sweeping tariffs and his push to get companies to move production inside the country’s borders. Read more…
A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for individuals living with Bardet-Biedl Syndrome (BBS), a rare genetic disorder characterized by early-onset obesity, compulsive eating, and cognitive impairments.
As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal policy In early April, CMS rejected a Biden-era proposal to allow Medicare coverage of GLP-1 medications when prescribed solely for weight loss. Medicare … Read more
A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and increased risk of depression and suicidal ideation, especially in people with low dopamine function. Researchers used advanced pharmacogenomic tools to identify genetic pathways that may be vulnerable to dopamine dysregulation when exposed to these medications.
Andrea Marcellus said there are some foods can can work as a natural Ozempic because they’re filled with nutrients that can stimulate the release of GLP-1, the hormone that regulates appetite.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today we talk about Eli Lilly’s stock jumping after it released new data on its GLP-1 pill, see Sanofi partner with a mysterious company, and more. Read the rest…
GLP-1 pill: Eli Lilly says its oral orforglipron showing “promising results” Axios Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar The New York Times A very good day for Lilly, and a bad day for Novo statnews.com Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with … Read more